FDA approves Signos glucose monitoring for weight loss

On Wednesday, the Food and Pharmaceutical Administration approved the first glucose monitoring system, especially for weight loss from the initial signals, and created a new option for Americans to manage their weight.

Popular drugs such as current treatment options to lose weight-GLP-1s and surgical interventions are limited to obesity or a certain BMI patients. Obesity drugs like Novo NordiskWegovy and Hand LillyIt can also be difficult to access due to its high costs, limited US insurance scope and limited supply.

However, now, you can buy a sign of a signos to access any patient system. It uses an AI platform and a ready -made glucose monitor or CGM. Dexcom To provide personalized, real -time data and lifestyle suggestions for weight management.

“There is now a solution that everyone can use to help weight loss journey, and you don’t have to be a certain number of pounds to use it. Average is available for the average American who needs it.” He said. “The average person may be five pounds to be lost or may be 100 kilos to lose. We are here to help them at any point of this journey.”

Obesity epidemic costs the US health system More than 170 billion dollars per yearAccording to disease control and prevention centers. Almost 74% of Americans are overweight or obese, Government Data says. Signos hopes that “most of us can make a real big dent on this curve to improve it.”

Customers Registering to Signos to choose Currently, a three -month or six -month plan, which costs $ 139 and $ 129, respectively. The company will send all the CGMs that a patient needs for the number of months in their chosen plan.

Insurers do not currently cover the system for weight management, but plans are part of the price of approximately $ 1,000 GLP-1s in Signos USA. Signos said, “This expects it to develop rapidly as it continues to expand to weight,” he said.

Signos can be used in combination with glp-1 or bariatric surgery, Foulad Fouladgar-Merer. Patients, to maintain weight loss after leaving a GLP-1 can use the system, he said.

CGMs are small sensors worn on the upper arm that follows glucose levels, especially for people with diabetes. These data are sent wirelessly to the Signos application, which allows patients to record food intake and exercise levels, as well as other information used by the AI platform to make suggestions.

In addition to helping people lose pounds, the system aims to help users understand how their bodies react to certain foods and exercise models and make the right behavioral changes to manage and maintain their weight in the long term.

Signos did not share how many patients are currently using the glucose monitoring system, but Fouladgar-Mercer said tens of thousands of people have tried it over time. Signos said that after the approval, he scaled the CGM inventory and software capacity for “processing on a very large scale”.